苏州亚盛药业有限公司 Ascentage Pharma Mediaroom

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2024-04-08 07:58 1007

Ascentage Pharma Announces 2023 Annual Results

SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2024-03-27 22:30 1909

AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2024-03-06 08:59 2669

Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

SUZHOU, China, and ROCKVILLE, Md., Jan. 16, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2024-01-17 12:10 3748

Ascentage Pharma Presented at 42nd Annual J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a comme...

2024-01-11 11:53 4323

Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 1, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2024-01-02 11:58 1648

Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting

SUZHOU, China and ROCKVILLE, Md., Dec. 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-15 11:14 1614

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP

SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-13 16:47 2156

Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety

SUZHOU, China and ROCKVILLE, Md., Dec. 11, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-12 09:41 2151

Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib

SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2023-12-11 13:30 1118

Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%

SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-11 13:14 1110

Live from ASH 2023 | Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR

SUZHOU, China and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-12-11 12:56 967

Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second annive...

2023-11-24 19:57 2078

ASH 2023 | Ascentage Pharma to Present Results from Three Clinical Studies of Bcl-2 Inhibitor Lisaftoclax (APG-2575), Including the First Data in AML and MM

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-11-03 09:15 519

ASH 2023 | For the Sixth Consecutive Year, Results from Multiple Clinical Studies of Olverembatinib Have Been Selected for Presentations, Including Two Oral Reports, at the 2023 ASH Annual Meeting

SUZHOU, China, and ROCKVILLE, Md., Nov. 2, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-11-03 09:10 479

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

SUZHOU, China and ROCKVILLE, Md., Oct. 23, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-10-23 19:56 1112

First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

SUZHOU, China and ROCKVILLE, Md., Oct. 17, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-10-18 10:11 1239

Ascentage Pharma and AstraZeneca Enter into Clinical Collaboration on the Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Combination with BTK Inhibitor Acalabrutinib in Treatment-Naïve Patients with First-Line CLL/SLL

SUZHOU, China, and ROCKVILLE, Md., Oct. 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2023-10-16 09:23 1780

Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE

ROCKVILLE, Md. and SUZHOU, China, Oct. 12, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2023-10-13 08:22 1386

Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL

ROCKVILLE, Md. and SUZHOU, China, Aug. 6, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2023-08-07 09:43 1634

Latest News